## 1. Threshold and market separation The proposed acquisition is for **$140 million**, so the transaction is **above the $100 million** premerger-filing threshold. The filing question therefore turns on the market screens. The facts state that industrial conductive yarn and medical conductive mesh are **separate product markets** because customers do not substitute between them. Counsel therefore must analyze each market separately and must **not combine the two markets** merely to dilute Alder Loom’s and Prism Thread’s shares. --- # A. Industrial conductive yarn ## 1. Combined share Alder Loom: **12%** Prism Thread: **8%** Combined premerger share: \[ 12\% + 8\% = 20\% \] So the parties’ combined share in industrial conductive yarn is **20%**. --- ## 2. Premerger HHI HHI is the sum of squared market shares. | Firm | Share | Squared share | |---|---:|---:| | Alder Loom | 12% | 144 | | Prism Thread | 8% | 64 | | Competitor A | 25% | 625 | | Competitor B | 20% | 400 | | Competitor C | 15% | 225 | | Competitor D | 10% | 100 | | Competitor E | 10% | 100 | | **Premerger HHI** | | **1,658** | Premerger HHI: \[ 12^2 + 8^2 + 25^2 + 20^2 + 15^2 + 10^2 + 10^2 = 1,658 \] --- ## 3. Postmerger HHI After the merger, Alder and Prism are combined into a single 20% firm. | Firm | Share | Squared share | |---|---:|---:| | Alder/Prism combined | 20% | 400 | | Competitor A | 25% | 625 | | Competitor B | 20% | 400 | | Competitor C | 15% | 225 | | Competitor D | 10% | 100 | | Competitor E | 10% | 100 | | **Postmerger HHI** | | **1,850** | Postmerger HHI: \[ 20^2 + 25^2 + 20^2 + 15^2 + 10^2 + 10^2 = 1,850 \] --- ## 4. HHI increase Combining two firms increases HHI by twice the product of their premerger shares: \[ \Delta HHI = 2 \times 12 \times 8 = 192 \] Check: \[ 1,850 - 1,658 = 192 \] So the HHI increase in industrial conductive yarn is **192 points**. --- ## 5. Filing trigger in industrial conductive yarn The transaction exceeds $100 million. A filing is required in this market if either: 1. Combined share is **at least 25%**; or 2. Postmerger HHI exceeds **1,800** and the HHI increase exceeds **200 points**. Here: - Combined share = **20%**, which is **below 25%**. - Postmerger HHI = **1,850**, which is **above 1,800**. - HHI increase = **192**, which is **not more than 200**. Therefore, **neither filing trigger applies in industrial conductive yarn**. --- ## 6. Structural presumption in industrial conductive yarn The structural presumption arises only when postmerger HHI is above 1,800 **and** the HHI increase is greater than 200. Here, the HHI increase is only 192. Therefore, **no structural presumption arises in industrial conductive yarn**. The market is close to the HHI screen, but under the supplied Corda rules it does not create the presumption and does not require a filing. --- # B. Medical conductive mesh ## 1. Verified market data Verified domestic market revenue: | Seller/revenue | Revenue | |---|---:| | Alder Loom | $18 million | | Prism Thread | $6 million | | Other verified sellers combined | $56 million | | **Verified domestic total** | **$80 million** | Alder and Prism combined verified medical-mesh revenue: \[ 18 + 6 = \$24 \text{ million} \] Claimed imported mesh revenue is not yet verified. Let: \[ I = \text{qualifying imported medical-mesh revenue, in millions of dollars} \] Qualifying imports are added to the market denominator. The verified market denominator therefore becomes: \[ 80 + I \] The prompt assumes Alder and Prism’s $24 million combined medical-mesh revenue is complete. --- ## 2. Medical-mesh combined-share formula The parties’ combined medical-mesh share is: \[ \text{Combined medical-mesh share} = \frac{24}{80 + I} \] In percent form: \[ \text{Combined medical-mesh share} = 100 \times \frac{24}{80 + I} \] Examples: - If \(I = 0\): \[ \frac{24}{80} = 30\% \] - If \(I = 16\): \[ \frac{24}{96} = 25\% \] - If \(I = 30\): \[ \frac{24}{110} \approx 21.8\% \] Thus the unverified range of $0 to $30 million spans both sides of the 25% filing threshold. --- ## 3. Exact import-revenue level at which combined share falls below 25% Set the combined share equal to 25%: \[ \frac{24}{80 + I} = 0.25 \] Solve: \[ 24 = 0.25(80 + I) \] \[ 24 = 20 + 0.25I \] \[ 4 = 0.25I \] \[ I = 16 \] So the boundary is **$16 million** of qualifying imported medical-mesh revenue. - If qualifying imports are **$16 million or less**, the combined medical-mesh share is **at least 25%**. - If qualifying imports are **more than $16 million**, the combined medical-mesh share is **below 25%**. - If qualifying imports are **exactly $16 million**, the combined share is **exactly 25%**, which still triggers the share screen because the rule uses “at least 25 percent.” Therefore, the exact import-revenue boundary is **$16,000,000**; the combined share falls below 25% only when qualifying imports exceed **$16,000,000**. --- # C. Why medical-mesh HHI cannot yet be calculated reliably HHI requires the squared market share of **each seller** in the relevant market: \[ HHI = \sum s_j^2 \] where \(s_j\) is the market share of each seller \(j\). For medical conductive mesh, we currently know: - Alder’s revenue: $18 million; - Prism’s revenue: $6 million; - Other verified domestic sellers combined: $56 million; - Qualifying imported revenue: unknown and unallocated. That is not enough to compute HHI reliably. The critical missing data are **seller-by-seller import revenues** and, for full HHI accuracy, a **seller-by-seller breakdown of the $56 million “other verified sellers”** category. The same total import figure can produce very different HHI outcomes depending on how it is distributed among sellers. For example, suppose qualifying imports are $30 million. - If all $30 million is sold by one imported seller, HHI will be much higher. - If the $30 million is spread across many small imported sellers, HHI will be much lower. Similarly, the $56 million in “other verified sellers” could represent one dominant competitor or many fragmented competitors. Aggregating them hides the concentration relevant to HHI. For a given import level \(I\), using only the totals, the postmerger HHI range would be roughly: \[ \text{Minimum possible postmerger HHI} \approx \left(100 \times \frac{24}{80 + I}\right)^2 \] if all nonparty sellers are highly fragmented, and: \[ \text{Maximum possible postmerger HHI} = \left(100 \times \frac{24}{80 + I}\right)^2 + \left(100 \times \frac{56 + I}{80 + I}\right)^2 \] if all nonparty revenue is concentrated in one seller. That range is too wide to support a reliable HHI conclusion. What can be calculated from a verified total import level \(I\) is the HHI **increase** caused by combining Alder and Prism, because their revenues are known: \[ \Delta HHI = 2 \left( 100 \times \frac{18}{80 + I} \right) \left( 100 \times \times \frac{6}{80 + I} \right) \] \[ \Delta HHI = \frac{2,160,000}{(80 + I)^2} \] But the postmerger HHI itself cannot be reliably calculated without seller-level data for the rest of the market. --- # D. Specific data needed to verify imports To verify qualifying imported medical-mesh revenue, counsel should obtain data sufficient to establish, for the measurement year: 1. **Measurement-year delivery into Corda** - Dates of sale, shipment, and delivery. - Evidence that the product was actually delivered into the relevant Corda market during the measurement year. - Exclusion of sales outside the market, transshipment without qualifying delivery, or sales outside the measurement year. 2. **Product identification** - Product descriptions, specifications, and model numbers. - Documentation distinguishing medical conductive mesh from unrelated textile products included in the same customs codes. - Technical or customer records confirming the product qualifies as medical conductive mesh. 3. **Import/customs records** - Customs declarations and entry summaries. - Importer records. - Bills of lading or shipping records. - Customs broker reports. - HS/customs codes, but only after filtering out unrelated textile products. 4. **Customer and sales records** - Invoices. - Purchase orders. - Customer receipts or confirmations. - Distributor or wholesaler sales records. - Importer-to-customer records sufficient to trace the product into the Corda market. 5. **Revenue measurement** - Quantities sold. - Prices. - Discounts, returns, and allowances. - Consistent revenue definition matching the $80 million verified domestic market. - Reconciliation to the $24 million verified Alder/Prism medical-mesh revenue to avoid double counting. 6. **Seller identity** - Identity of the seller of record for each qualifying import. - Whether the seller is domestic or foreign. - Allocation of import revenue by seller. - Avoidance of double counting importers, distributors, and manufacturers. 7. **Seller-level HHI data** - If the HHI screen may be relevant, seller-by-seller import revenue is necessary. - Seller-by-seller domestic revenue for the $56 million “other verified sellers” group is also needed for a reliable HHI calculation. The specialist’s ten-day work should therefore be scoped not only to produce a total import figure but, if possible, to produce **seller-level qualifying import revenue** and a reliable reconciliation to the verified domestic market. --- # E. Filing and gun-jumping consequences ## 1. Filing consequence A premerger filing is required before closing if either trigger is met in any properly defined market. - In industrial conductive yarn, no trigger is met. - In medical conductive mesh, the answer depends on verified qualifying imports and, if the 25% share screen is not met, on the HHI screen. If a filing is required and the parties close without filing, each party is exposed to: \[ \$40,000 \text{ per day} \] from closing until compliance. So if the parties close and remain noncompliant for \(d\) days: - Penalty per party: \[ \$40,000 \times d \] - Combined penalty for both parties: \[ \$80,000 \times d \] For example, if they close and file three days later: - Each party: \(3 \times \$40,000 = \$120,000\) - Combined: \(3 \times \$80,000 = \$240,000\) This penalty rule makes it especially important not to close before a required filing is made. --- ## 2. Gun-jumping consequence Even if a filing were not required, Alder and Prism remain separate competitors before closing. Gun-jumping concerns include, depending on the facts: - Premature integration of operations; - Exchange of competitively sensitive information beyond permissible due diligence; - Coordination on price, customers, output, or market allocation; - Transfer of operational control before closing; - Making binding competitive decisions jointly as if the parties were already one firm. Filing does not eliminate gun-jumping risk. A required filing must be made before closing, and the parties must still preserve independent competitive decision-making until closing. Also, a filing does **not** concede illegality. If the parties file, they may later present entry, expansion, efficiencies, failing-firm, or remedy evidence when supported by the record. --- # F. Medical-mesh filing decision tree Let \(I\) be verified qualifying imported medical-mesh revenue, in millions of dollars. There are two important medical-mesh boundaries: 1. **25% combined-share boundary:** \[ I = 16 \] 2. **HHI-increase boundary:** \[ \Delta HHI > 200 \] Using: \[ \Delta HHI = \frac{2,160,000}{(80 + I)^2} \] Set \(\Delta HHI = 200\): \[ \frac{2,160,000}{(80 + I)^2} = 200 \] \[ (80 + I)^2 = 10,800 \] \[ 80 + I = \sqrt{10,800} \approx 103.923 \] \[ I \approx 23.923 \] So: - If \(I < 23.923\), the HHI increase is **greater than 200**. - If \(I = 23.923\), the HHI increase is **exactly 200**, which is not enough. - If \(I > 23.923\), the HHI increase is **less than 200**. The practical decision tree is: | Verified qualifying imports \(I\) | Combined medical share | Share trigger? | HHI increase | HHI trigger? | Filing recommendation | |---:|---:|---:|---:|---|---| | \(I \le 16\) | \(\ge 25\%\) | Yes | \(> 200\) | Unknown without seller-level HHI; structural presumption only if postmerger HHI > 1,800 | **Filing required** before closing | | \(16 < I < 23.923\) | \(< 25\%\) | No | \(> 200\) | Yes if postmerger HHI > 1,800; no if postmerger HHI \(\le 1,800\) | **File if postmerger HHI > 1,800**; if HHI cannot be reliably calculated before closing, **file conservatively** | | \(I \ge 23.923\) | \(< 25\%\) | No | \(\le 200\) | No, regardless of postmerger HHI concentration | **No medical-mesh filing trigger**, assuming no industrial trigger | Important boundary notes: - At exactly \(I = 16\), combined share is exactly 25%, so the share trigger applies. - At exactly \(I \approx 23.923\), the HHI increase is exactly 200, which is not “more than 200,” so the HHI trigger does not apply. - The 25% share screen requires a filing but does **not** itself create the structural presumption. The structural presumption requires the HHI screen. --- # G. Recommendation Management’s argument that no filing is needed because “imports probably push us below 25 percent” is not legally sufficient. The plausible but unverified import range is $0 to $30 million. That range includes: - $0, which yields a 30% combined medical-mesh share; - $16 million or less, which yields at least a 25% combined share; - and higher import levels that may avoid the 25% screen but may still leave HHI uncertainty. Counsel may not assume the missing input in the direction preferred by the client. The missing import figure is known and obtainable, and it materially affects the filing analysis. ## Recommended course **Do not proceed without filing.** I recommend a conservative filing now, while the ten-day import verification is completed and the filing is supplemented afterward. Reasons: 1. The current verified medical-mesh record already shows a **30% combined share**, because only $80 million of market revenue is verified and the parties have $24 million of it. 2. The missing import figure could be **$16 million or less**, in which case the 25% combined-share trigger is met. 3. Even if verified imports exceed $16 million, the HHI trigger may still exist for import levels below approximately **$23.923 million**, and the medical-mesh HHI cannot yet be calculated reliably. 4. Filing now does not concede illegality and preserves the parties’ ability to present defenses later if supported. 5. The parties plan to close in 35 days. Filing now reduces the risk of missing the filing deadline or later discovering that a filing was required. If the parties insist on avoiding a potentially unnecessary filing, the only acceptable alternative is: 1. Complete the ten-day import verification before making any no-filing decision; 2. Ensure there is sufficient time to file before closing if a trigger is found; and 3. Apply the decision tree above. In no event should the parties close based on unverified “probably” imports. ## Concrete conditional recommendation - **If verified qualifying imports are $16 million or less:** The medical-mesh combined share is at least 25%. A filing is required. File before closing and do not close until the filing requirement is satisfied. - **If verified qualifying imports are more than $16 million but less than approximately $23.923 million:** The combined-share screen is not met, but the HHI increase exceeds 200. Compute postmerger HHI using seller-level data. If postmerger HHI exceeds 1,800, file. If postmerger HHI is 1,800 or less, no medical-mesh filing trigger arises under the supplied rules. If seller-level HHI data cannot be obtained before closing, file conservatively. - **If verified qualifying imports are $23.923 million or more:** The combined medical-mesh share is below 25%, and the HHI increase is not more than 200. No medical-mesh filing trigger arises under the supplied rules, and the industrial market does not trigger a filing. The parties may proceed without a medical-mesh filing, but they must still avoid gun-jumping before closing. ## If the parties sign next week Signing before filing is not necessarily prohibited, but the agreement and conduct should reflect: - A closing condition requiring any necessary premerger filing and satisfaction of any applicable waiting or clearance requirement; - No premature integration or coordination; - Continued separate competitive decision-making by Alder and Prism; - Strict controls on information exchange and integration planning before closing. Bottom line: **file conservatively now or, at the latest, file before closing if the verified import data trigger any screen. Do not close on the basis of unverified import assumptions.**